Host Impairments in Patients with Neoplastic Diseases

Overview

Journal Cancer Treat Res

Publisher Springer

Specialties Oncology
Pharmacology

Date 2014 Apr 8

PMID 24706220

Citations 10

Authors

J Peter Donnelly

Nicole M A Blijlevens

Walter J F M van der Velden

Affiliations

Soon will be listed here.

Abstract

Healthy individuals possess an immune system comprising physical barriers, innate and acquired immunity as well as the indigenous microflora that populate the body surfaces. The immune system maintains constant vigilance over the body at the cellular level as well as at the interface between the host integument and the resident microflora. However, neoplastic diseases and their treatment often lead to impaired immunity resulting in an increased risk of infections due to viruses, bacteria, fungi, and protozoa. This chapter explores the various aspects of host impairment focusing on the components of immunity and the interplay between them to explain why it is that these patients succumb to infections per se. In so doing, we hope that the reader will be better equipped to understand the risks patients face so as to anticipate potential infectious complications and implement appropriate measures to help attain successful remission of the neoplastic diseases and maintain the best quality of life for the patient.

Citing Articles

Recommendations for broadening eligibility criteria in esophagus cancer clinical trials: the mortality disparity of esophagus cancer as a first or second primary malignancy.

Leng J, Qiu H, Huang Q, Zhang J, Zhou H J Thorac Dis. 2024; 16(6):3882-3896.

PMID: 38983155 PMC: 11228734. DOI: 10.21037/jtd-23-1881.

High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma.

OReilly M, Neill L, Collin S, Stone N, Springell D, Mensah J Hemasphere. 2024; 8(1):e29.

PMID: 38434533 PMC: 10878197. DOI: 10.1002/hem3.29.

Non cancer causes of death after gallbladder cancer diagnosis: a population-based analysis.

Xia Y, Lu S, Huo C, Fan L, Lin M, Huang J Sci Rep. 2023; 13(1):13746.

PMID: 37612302 PMC: 10447554. DOI: 10.1038/s41598-023-40134-4.

Roles of Toll-Like Receptors in Radiotherapy- and Chemotherapy-Induced Oral Mucositis: A Concise Review.

Ji L, Hao S, Wang J, Zou J, Wang Y Front Cell Infect Microbiol. 2022; 12:831387.

PMID: 35719331 PMC: 9201217. DOI: 10.3389/fcimb.2022.831387.

Immediate risk of non-cancer deaths after a cancer diagnosis.

Yang P, Zheng Y, Chen J, Ma H, Yu K, Chen Y BMC Cancer. 2021; 21(1):963.

PMID: 34452598 PMC: 8394256. DOI: 10.1186/s12885-021-08707-6.

References

Backhed F, Ley R, Sonnenburg J, Peterson D, Gordon J . Host-bacterial mutualism in the human intestine. Science. 2005; 307(5717):1915-20. DOI: 10.1126/science.1104816. View

Lanier L . Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008; 9(5):495-502. PMC: 2669298. DOI: 10.1038/ni1581. View

Bodey G, Bueltmann B, Duguid W, Gibbs D, Hanak H, Hotchi M . Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis. 1992; 11(2):99-109. DOI: 10.1007/BF01967060. View

Bow E, Loewen R, Cheang M, Shore T, Rubinger M, Schacter B . Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. J Clin Oncol. 1997; 15(6):2254-61. DOI: 10.1200/JCO.1997.15.6.2254. View

Donnelly J, Maschmeyer G, Daenen S . Selective oral antimicrobial prophylaxis for the prevention of infection in acute leukaemia-ciprofloxacin versus co-trimoxazole plus colistin. The EORTC-Gnotobiotic Project Group. Eur J Cancer. 1992; 28A(4-5):873-8. DOI: 10.1016/0959-8049(92)90138-r. View

Clasener H, Vollaard E, Van Saene H . Long-term prophylaxis of infection by selective decontamination in leukopenia and in mechanical ventilation. Rev Infect Dis. 1987; 9(2):295-328. DOI: 10.1093/clinids/9.2.295. View

Chayakulkeeree M, Ghannoum M, Perfect J . Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis. 2006; 25(4):215-29. DOI: 10.1007/s10096-006-0107-1. View

Schimpff S, Gaya H, Klastersky J, Tattersall M, Zinner S . Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC international antimicrobial therapy project group. J Infect Dis. 1978; 137(1):14-29. View

Donnelly J, Muus P, Schattenberg A, de Witte T, Horrevorts A, DePauw B . A scheme for daily monitoring of oral mucositis in allogeneic BMT recipients. Bone Marrow Transplant. 1992; 9(6):409-13. View

10.

Pitman R, Blumberg R . First line of defense: the role of the intestinal epithelium as an active component of the mucosal immune system. J Gastroenterol. 2000; 35(11):805-14. DOI: 10.1007/s005350070017. View

11.

Sansonetti P . Host-bacteria homeostasis in the healthy and inflamed gut. Curr Opin Gastroenterol. 2008; 24(4):435-9. DOI: 10.1097/MOG.0b013e32830007f7. View

12.

Schimpff S . Infection prevention during profound granulocytopenia. New approaches to alimentary canal microbial suppression. Ann Intern Med. 1980; 93(2):358-61. DOI: 10.7326/0003-4819-93-2-358. View

13.

Donnelly J, Dompeling E, Meis J, De Pauw B . Bacteremia due to oral viridans streptococci in neutropenic patients with cancer: cytostatics are a more important risk factor than antibacterial prophylaxis. Clin Infect Dis. 1995; 20(2):469-70. DOI: 10.1093/clinids/20.2.469. View

14.

Bodey G, Buckley M, SATHE Y, Freireich E . Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966; 64(2):328-40. DOI: 10.7326/0003-4819-64-2-328. View

15.

Sonis S . The pathobiology of mucositis. Nat Rev Cancer. 2004; 4(4):277-84. DOI: 10.1038/nrc1318. View

16.

Vollaard E, Clasener H, Janssen A . Decontamination of the bowel by intravenous administration of pefloxacin. J Antimicrob Chemother. 1990; 26(6):847-52. DOI: 10.1093/jac/26.6.847. View

17.

Bochud P, Eggiman P, Calandra T, van Melle G, Saghafi L, Francioli P . Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis. 1994; 18(1):25-31. DOI: 10.1093/clinids/18.1.25. View

18.

Cometta A, Calandra T, Bille J, Glauser M . Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med. 1994; 330(17):1240-1. DOI: 10.1056/NEJM199404283301717. View

19.

Ferrara J, Levine J, Reddy P, Holler E . Graft-versus-host disease. Lancet. 2009; 373(9674):1550-61. PMC: 2735047. DOI: 10.1016/S0140-6736(09)60237-3. View

20.

Johnson S, Driks M, Tweten R, Ballard J, Stevens D, Anderson D . Clinical courses of seven survivors of Clostridium septicum infection and their immunologic responses to alpha toxin. Clin Infect Dis. 1994; 19(4):761-4. DOI: 10.1093/clinids/19.4.761. View